 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- KPG-121 / Kangpu Biopharma
A case report of metastatic castration resistant prostate cancer patient with AR F877L mutation treated with KPG-121 in combination with enzalutamide (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1227;
P1
than lenalidomide in vitro...The patient had a medical history of osteoarthritis and his prior treatments included bicalutamide, leuprorelin, sipuleucel-T, enzalutamide, and intensity-modulated radiotherapy. The patient
- || KPG-121 / Kangpu Biopharma
Trial completion, Metastases: Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients (clinicaltrials.gov) - Jul 18, 2023
P1, N=16, Completed, Sponsor: Kangpu Biopharmaceuticals, Ltd.
The patient Active, not recruiting --> Completed
- || KPG-121 / Kangpu Biopharma
Enrollment closed, Enrollment change, Trial completion date, Metastases: Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients (clinicaltrials.gov) - Feb 23, 2023
P1, N=16, Active, not recruiting, Sponsor: Kangpu Biopharmaceuticals, Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=36 --> 16 | Trial completion date: Dec 2022 --> Apr 2023
- | KPG-121 / Kangpu Biopharma
Trial completion date, Trial primary completion date, Metastases: Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients (clinicaltrials.gov) - Apr 6, 2022
P1, N=36, Recruiting, Sponsor: Kangpu Biopharmaceuticals, Ltd.
Recruiting --> Active, not recruiting | N=36 --> 16 | Trial completion date: Dec 2022 --> Apr 2023 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- | KPG-121 / Kangpu Biopharma
Trial completion date, Trial primary completion date, Metastases: Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients (clinicaltrials.gov) - Feb 21, 2021
P1, N=36, Recruiting, Sponsor: Kangpu Biopharmaceuticals, Ltd.
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- KPG-121 / Kangpu Biopharma
[VIRTUAL] KPG-121, a novel CRBN modulator, potently inhibits growth of metastatic castration resistant prostate cancer as a single agent or in combination with androgen receptor signaling inhibitors both in vitro and in vivo (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_4029;
Results from in vivo metastatic castration resistant prostate cancer xenograft models demonstrated that KPG-121 at tested daily dose levels ranging from 1.0 mg/kg to 10 mg/kg in combination with Enzalutamide, Abiraterone Acetate, Apalutamide or Darolutamide significantly improved anti-tumor efficacy compared to the AR signaling inhibitors alone. In addition, KPG-121 showed favorable DMPK profiles and potentially manageable toxicity in pre-clinical IND enabling study.
- | KPG-121 / Kangpu Biopharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients (clinicaltrials.gov) - Nov 15, 2019
P1, N=36, Recruiting, Sponsor: Kangpu Biopharmaceuticals, Ltd.
In addition, KPG-121 showed favorable DMPK profiles and potentially manageable toxicity in pre-clinical IND enabling study. Trial completion date: Dec 2022 --> Dec 2020 | Trial primary completion date: Jun 2021 --> Dec 2020
- | KPG-121 / Kangpu Biopharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients (clinicaltrials.gov) - Aug 14, 2019
P1, N=36, Recruiting, Sponsor: Kangpu Biopharmaceuticals, Ltd.
Trial completion date: Dec 2022 --> Dec 2020 | Trial primary completion date: Jun 2021 --> Dec 2020 Trial completion date: Jun 2020 --> Dec 2022 | Trial primary completion date: Oct 2019 --> Jun 2021
- || KPG-121 / Kangpu Biopharma
Trial initiation date, Combination therapy, Metastases: Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients (clinicaltrials.gov) - May 15, 2019
P1, N=36, Recruiting, Sponsor: Kangpu Biopharmaceuticals, Ltd.
Trial completion date: Jun 2020 --> Dec 2022 | Trial primary completion date: Oct 2019 --> Jun 2021 Initiation date: Oct 2018 --> May 2019
- | KPG-121 / Kangpu Biopharma
Enrollment change, Combination therapy, Metastases: Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients (clinicaltrials.gov) - Aug 29, 2018
P1, N=36, Recruiting, Sponsor: Kangpu Biopharmaceuticals, Ltd.
Initiation date: Oct 2018 --> May 2019 N=24 --> 36
- || KPG-121 / Kangpu Biopharma
New P1 trial, Combination therapy, Metastases: Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients (clinicaltrials.gov) - Jul 15, 2018
P1, N=24, Recruiting, Sponsor: Kangpu Biopharmaceuticals, Ltd.